http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109071671-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 |
| filingDate | 2017-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109071671-B |
| titleOfInvention | ERBB2 targeting antibody |
| abstract | The present invention relates to an antibody, in particular a monoclonal antibody, that binds to a neo-epitope of the ERBB2 tyrosine kinase receptor, wherein the unique nature of the binding enables novel and novel antibodies not available with prior art therapeutic antibodies Interfere with receptor-mediated signaling and downstream biological effects in unexpected ways. The present invention relates to compositions comprising such antibodies and humanized derivatives thereof, and especially in combination with Trastuzumab and Pertuzumab, in particular in ERBB2-low/non-amplifying breast cancer Methods of such antibodies and derivatives. |
| priorityDate | 2016-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 293.